The EIF has invested €25m in the Prague-based i&i Biotech Fund I to boost biomedical tech transfer in Austria and Eastern Europe.
Boehringer Ingelheim has acquired Texan biotech Abexxa Biologics Inc., further expanding its cancer immunotherapy pipeline.
Following the $39bn Alexion buy-out completed in July, AstraZeneca plc announced it will invest €307m in the company’s producion site near Dublin.
Bayer AG has joined forces with young Danish biotech Gubra ApS in a research collaboration and license agreement for the development of peptide therapeutics to treat cardiorenal diseases.
The Novo Nordisk Foundation is investing US$47.5m into a research collaboration with the Broad Institute of MIT and Harvard, intending to dive into the disease mechanisms of diabetes and obesity.
UK-based DNA synthesis specialist Touchlight Ltd has extended a funding round to a current aggregate total of US $125m.
Royal DSM is backing Meatable, the cultivated meat start-up, in order to develop growth media for cultivated meat.
EnteroBiotix closes an oversubscribed Series A financing with US$21.5m. The biopharma company will use the proceeds to advance its microbiome drug pipeline.
The Swiss biopharmaceutical industry is on the verge of record growth: This was demonstrated at the live Swiss Biotech Day in Basel.
Owlstone Medical has raised US$59m in a Series D financing round. The proceeds will be used to continue development of the companys breath biopsy tests.